GlassScriptPhysician profile
Blessey M Joseph
NPI 1265844195
$14,527.25
in general payments reported to CMS, 2019-2025
46 companies · $4,156 in 2025
The $4,156 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $636 · 2021: $1,168 · 2022: $1,863 · 2023: $1,924 · 2024: $4,012 · 2025: $4,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,022.67 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,950.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,537.42 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,302.22 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,199.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,079.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $715.84 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $683.11 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $590.55 | 2022-2025 | Repatha, Evenity, Prolia |
| Abbott Laboratories | $445.88 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $386.02 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $347.71 | 2019-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $310.82 | 2021-2025 | Zoryve |
| Pfizer INC. | $286.20 | 2023-2025 | |
| Scilex Pharmaceuticals INC. | $270.54 | 2023-2025 | Elyxyb |
| Astellas Pharma US INC | $254.12 | 2024-2025 | Veozah |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $245.85 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $240.36 | 2019-2025 | Verquvo |
| Otsuka America Pharmaceutical, INC. | $236.97 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $223.81 | 2022-2025 | |
| Ardelyx, INC. | $200.49 | 2024-2025 | Ibsrela |
| Exact Sciences Corporation | $199.67 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $175.26 | 2025 | Symbravo, Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $159.47 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $157.28 | 2025 | Caplyta |
| Lundbeck LLC | $153.03 | 2024-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $144.49 | 2025 | Gemtesa, Myfembree |
| Amneal Pharmaceuticals LLC | $129.75 | 2022-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $107.84 | 2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $101.27 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $95.82 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $86.16 | 2022-2025 | Eliquis, Camzyos |
| Corcept Therapeutics | $81.14 | 2024 | Korlym |
| Medicomp INC | $55.89 | 2024 | Telepatch Cardiac Monitor |
| Shield Therapeutics INC | $53.11 | 2023-2025 | Accrufer |
| Heartflow, INC. | $43.74 | 2023-2024 | Ffrct |
| Edwards Lifesciences Corporation | $43.47 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $40.66 | 2019-2023 | |
| Phadia US INC. | $33.66 | 2023-2024 | Immunocap |
| Althera Pharmaceuticals LLC | $31.09 | 2021 | |
| Genzyme Corporation | $24.92 | 2024 | |
| Ironwood Pharmaceuticals, INC | $20.62 | 2023 | Linzess |
| Renalytix Ai, INC. | $18.37 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Scpharmaceuticals INC. | $17.96 | 2025 | |
| Paratek Pharmaceuticals, INC. | $15.42 | 2025 | Xhance, Nuzyra |
| Genentech USA, INC. | $15.18 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blessey Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.